Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN -0.93%21 3-Year ROIIC % is 0.23 as of Dec. 2025, which is at its 10-year median of 0.23. GuruFocus rates BKK:TMAN with a GF Score™ of 21/100. Among 943 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks worse than 56.2% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
T.MAN Pharmaceutical PCL's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 0.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for T.MAN Pharmaceutical PCL's 3-Year ROIIC % or its related term are showing as below:
BKK:TMAN's 3-Year ROIIC % is ranked worse than 56.2% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs BKK:TMAN: 0.23
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
T.MAN Pharmaceutical PCL 3-Year ROIIC % Related Terms
T.MAN Pharmaceutical PCL 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:TMAN vs ZTS, UTHR, VTRS: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
T.MAN Pharmaceutical PCL (BKK:TMAN) has a 3-Year ROIIC % of 0.23 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is near median its historical median of 0.23. Over the past decade, T.MAN Pharmaceutical PCL's 3-Year ROIIC % has ranged from 0.23 to 0.23. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #530 out of 943 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is T.MAN Pharmaceutical PCL's 3-Year ROIIC % too high?
T.MAN Pharmaceutical PCL's current 3-Year ROIIC % of 0.23 is near median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.23. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. T.MAN Pharmaceutical PCL's value of 0.23 is 93.5% below this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #530 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #530 out of 943 companies for 3-Year ROIIC %. This places T.MAN Pharmaceutical PCL in the lower half of its industry. The industry median 3-Year ROIIC % is 3.56. T.MAN Pharmaceutical PCL's value of 0.23 is 93.5% below this benchmark. Historically, T.MAN Pharmaceutical PCL's own 3-Year ROIIC % has ranged from 0.23 to 0.23 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 3.56, T.MAN Pharmaceutical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current 3-Year ROIIC % of 0.23 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current 3-Year ROIIC % is 0.23, which is near median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current 3-Year ROIIC % of 0.23. The current 3-Year ROIIC % is 0.23, which is near median its 10-year median of 0.23 and 93.5% below the Drug Manufacturers industry median of 3.56. T.MAN Pharmaceutical PCL's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current 3-Year ROIIC % is 0.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
21GF Score
Get the complete analysis for BKK:TMAN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
